SCHEMBL1742818

SCHEMBL1742818

O=C(NCc1ccc(S(=O)(=O)Cl)s1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
LOX P28300 2/20 0.51
CCKBR P32239 1/20 0.48
BCL2 P10415 1/20 0.45
BCL2L1 Q07817 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.44
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CA2 P00918 1/20 0.43
HDAC3 O15379 1/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL924672 0.87 MAPK9 (0.49) MEN1KMT2ALOXBCL2BCL2L1
SCHEMBL8033818 0.87 HPGD (0.54) HPGDMEN1KMT2ALOXCCKBR
SCHEMBL13881587 0.86 MEN1 (0.54) HPGDMEN1KMT2ALOXCCKBR
SCHEMBL1742958 0.86 HPGD (0.52) HPGDMEN1KMT2ALOXCCKBR
Hydrochloric Acid SCHEMBL28187724 0.86 HPGD (0.52) HPGDMEN1KMT2ALOXCCKBR
SCHEMBL7460244 0.82 CCKBR (0.50) HPGDMEN1KMT2ALOXCCKBR
SCHEMBL14519924 0.82 MEN1 (0.52) HPGDMEN1KMT2ALOXCCKBR
SCHEMBL4318736 0.81 MMP13 (0.54) HPGDMEN1KMT2ALOXGAA
SCHEMBL7451657 0.81 MEN1 (0.51) HPGDMEN1KMT2ALOXCCKBR
SCHEMBL3008054 0.79 MAPT (0.55) MEN1KMT2ALOXMAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 US disclosed
CN-104168958-B Diaryl sulfonamides useful for the treatment of inflammation and cancer 坎塞拉有限公司 2017-12-01 CN disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 US disclosed
EP-3095784-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Inc. (US) 2016-11-23 EP disclosed
US-9493431-B2 Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2016-11-15 US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 US disclosed
EP-2387559-B1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2016-06-29 EP disclosed
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-20160002187-A1 APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2016-01-07 US disclosed
US-6084130-A FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY (US) 2000-07-04 US disclosed
WO-2000035904-A1 INHIBITORS OF β-LACTAMASES AND USES THEREFOR NORTHWESTERN UNIVERSITY (US) 2000-06-22 WO disclosed
WO-2000020440-A1 CASPASES AND APOPTOSIS SMITHKLINE BEECHAM CORPORATION (US) 2000-04-13 WO disclosed
EP-0923542-A1 ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1999-06-23 EP disclosed
US-5877196-A N- 4-(imidazolyl or pyrazolyl)phenyl(oxy, sulfinyl, sulfenyl or sulfonyl)alkyl!carboxamides, sulfonamides or phosphoramides having antiarrhythmic properties AMERICAN CYANAMID COMPANY (US) 1999-03-02 US disclosed
WO-1997045403-A1 ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1997-12-04 WO disclosed
EP-0792873-A1 N-(Phenoxyalkyl) carboxamides and their use as antiarrhythmic agents American Cyanamid Company (US) 1997-09-03 EP disclosed
EP-0456073-B1 Multifunctional compounds having alpha-diazo-beta-ketoester units and sulfonic acid ester units and process for their preparation. HOECHST AG (DE) 1995-10-25 EP disclosed
US-5191069-A Photosensitive compounds with heat resistance HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-02 US disclosed
EP-0456073-A2 Multifunctional compounds having alpha-diazo-beta-ketoester units and sulfonic acid ester units and process for their preparation. HOECHST AKTIENGESELLSCHAFT (DE) 1991-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF HPGD 1246/4885MEN1 4261/4885KMT2A 3165/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF HPGD 1246/4885MEN1 4261/4885KMT2A 3165/4885
US-20160002187-A1 APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BCL2, BAX, BCL3 HPGD 1633/4885MEN1 3625/4885KMT2A 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.